Bull Of The Day: OptimizeRX (OPRX)

Core Viewpoint - OptimizeRX (OPRX) is a small-cap company with a strong growth outlook, currently holding a Zacks Rank 1 (Strong Buy) and an A for Growth, despite having an F for Value [1] Company Overview - OptimizeRX Corporation operates a health solutions platform aimed at helping patients and physicians afford and comply with medications and healthcare products [2] - The company connects patients, physicians, and pharmaceutical manufacturers through its consumer websites, providing marketing and advertising solutions [2] Earnings History - OptimizeRX has achieved four consecutive earnings beats against the Zacks Consensus Estimate, with an average positive earnings surprise of 105% over the last year [4] - The latest earnings report showed a profit of $0.08, surpassing the consensus estimate of -$0.11 by 19 cents, resulting in a positive earnings surprise of 172% [4] Earnings Estimates Revisions - Earnings estimates for OptimizeRX have been revised upward, with the full year 2025 estimate increasing from $0.51 to $0.54 and the 2026 estimate rising from $0.66 to $0.68 over the past 60 days [5] Growth Projections - Analysts project revenue of $103 million for the current fiscal year, reflecting a 12.7% growth [6] - For the next fiscal year, the consensus anticipates revenue of $117 million, indicating a growth rate of 12.6% [6] Valuation Metrics - The forward price-to-earnings (PE) ratio for OptimizeRX is slightly above the market average at 23x, while the price-to-book ratio is low at 2x, appealing to value-oriented investors [7] - The price-to-sales ratio stands at 2.5x, and margins have improved from -3.1% to -0.2% over the last two quarters, with expectations for positive margins in the upcoming earnings report [7]